GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)
Malignant Hydrothorax
Xinqiao Hospital of Chongqinggene_therapyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Hydrothorax cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Xinqiao Hospital of Chongqing | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Xinqiao Hospital of Chongqing | Phase 3 | B |
Vinorelbine Xinqiao Hospital of Chongqing | Phase 3 | B |
Endostar Xinqiao Hospital of Chongqing | Phase 3 | B |
Same molecule, other indications
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →